DZ-002 for Cancer
Trial Summary
What is the purpose of this trial?
This trial tests DZ-002, a new drug for cancer patients whose standard treatments didn't work. It involves regular IV doses to check safety, body behavior, and tumor effects.
Do I have to stop taking my current medications for the trial?
The trial requires stopping certain medications. You must stop taking simvastatin and any strong inhibitors or inducers of CYP3A4, CYP2B6, CYP1A2, CYP2C9, and CYP2C8 before and during the study. If you're on these, discuss with your doctor.
Will I have to stop taking my current medications?
The trial requires stopping certain medications, such as simvastatin and strong inhibitors or inducers of specific enzymes (CYP3A4, CYP2B6, CYP1A2, CYP2C9, and CYP2C8), before and during the study. If you are on these medications, you may need to stop them to participate.
What data supports the idea that DZ-002 for Cancer is an effective treatment?
What safety data is available for DZ-002 in cancer treatment?
The provided research does not contain specific safety data for DZ-002 or its variants (dz-002, dz 002, dz002). The studies focus on other treatments such as atezolizumab, ipilimumab, and avelumab, as well as PD-1/PD-L1 inhibitors and HER2-targeted therapies. Therefore, no safety data for DZ-002 is available in the given research.678910
Research Team
Robert L De Jager, MD
Principal Investigator
Dazen Theranostics
Eligibility Criteria
Adults with advanced solid tumors or lymphoma that haven't responded to standard treatments can join this trial. They must be able to follow the study plan, have a life expectancy over 8 weeks, and good organ function. Women of childbearing age need a negative pregnancy test and agree to use birth control.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of DZ-002 in patients with advanced cancers
Dose Expansion
Investigate the MTD and/or RP2D in two expansion treatment groups: castration-resistant prostate cancer and advanced pancreatic cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- DZ-002
Find a Clinic Near You
Who Is Running the Clinical Trial?
Da Zen Theranostics Inc
Lead Sponsor